Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > REGULATORY
REGULATORY
- LDP League, MHLW Discussing to Create Forum to Study SaMD Reimbursement
December 13, 2022
- Paper Retraction Won’t Impact Zolgensma Japan Approval, Data Deleted from Label
December 13, 2022
- Yescarta, Breyanzi Clear Panel Review for Second-Line Use
December 13, 2022
- Japan Panel Recognizes 5 More Deaths Possibly Linked to COVID Jabs, 1st for 20s
December 13, 2022
- Japan’s Diet Enacts Bill to Amend Intractable Disease Law
December 13, 2022
- Add New Evaluation Elements in Granting Launch Premiums: Expert Panel
December 12, 2022
- Market Expansion Re-Pricing Has Gone Overboard with Spillover Rule, Experts Say
December 12, 2022
- Revisit PMP Company Criteria to Support Innovation from Foreign Biotechs: Experts
December 12, 2022
- Experts Call for New Drug Pricing Rule for Innovative Medicines, No Objections Raised
December 12, 2022
- 70% of Listed Meds Likely to Face Off-Year Re-Pricing If Prior Threshold Applied: MHLW
December 12, 2022
- Keytruda Gets Orphan Tag for PMBCL in Japan
December 12, 2022
- First Generics for 5 APIs Join NHI Price List, Main Targets Are Nexium/Lexapro
December 9, 2022
- Panel OKs Moderna Boosters for Age 12 and Up
December 9, 2022
- Industry Prods Special Inflation Measure in Off Year, Payers Don’t See Much Need: Chuikyo Hearing
December 8, 2022
- Japan Offers Mpox Vaccines to Columbia for Free
December 8, 2022
- Man Sues PMDA over Rejected Relief Claim for “Ranitidine Caused Cancer”
December 7, 2022
- Lilly’s Insulin Lyumjev Gets Label Update for Pediatric Use
December 7, 2022
- Delete Contraindications on Use of Amlodipine, Nifedipine in Pregnant Women: MHLW
December 6, 2022
- Susmed’s Insomnia App Up for PAFSC Review on December 19
December 6, 2022
- PAFSC Committee OKs Plan to Monitor Early Safety Signals from Xocova Using MID-NET
December 5, 2022
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…